27 January 2021 - - US-based biotechnology company Moderna, Inc. (NASDAQ: MRNA) is in discussion with the US government to purchase an additional 100m doses of the Moderna COVID-19 Vaccine for delivery in the third quarter of 2021, the company has confirmed.

To date, the US government has agreed to purchase 200m doses of the Moderna COVID-19 Vaccine.

This new purchase would bring the US government's confirmed order commitment to 300 m doses.
Moderna will continue to leverage the company's US-based manufacturing infrastructure to supply the Moderna COVID-19 Vaccine to the US government.

The Moderna COVID-19 Vaccine received Emergency Use Authorization from the US Food and Drug Administration on December 18, 2020 and Moderna began supplying to the government shortly thereafter.

The Moderna COVID-19 Vaccine has been authorized for emergency use by the US Food and Drug Administration for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.